Abstract
Introduction
The benefits that neoadjuvant chemotherapy (NAC) provides in treating patients with breast cancer are well known. However, its effects on axillary lymph nodes and lymph node yield (LNY) following axillary lymph node dissection (ALND) remain unclear. Given the importance of LNY for accurate axillary staging in patients with breast cancer, we retrospectively reviewed a large national cancer database to determine if NAC has an effect on LNY following axillary surgery.
Methods
A retrospective review of the National Cancer Database was performed. Patients diagnosed from 2010 to 2015 with T0–T4, clinical N0–3, and M0 breast cancer who underwent ALND were included. Patients were categorized by NAC and primary surgery (PS). A descriptive analysis of patient and tumor characteristics, as well as extrinsic factors, was performed. A univariate analysis using Student’s t-test was performed to evaluate LNY between the two groups.
Results
A total of 118,108 patients were included in our study. We found that 29,066 (24.6%) patients underwent NAC, and 89,042 (75.4%) had surgery as initial treatment (PS group). The median LNY by ALND in the NAC group was 11 (Q1, Q3: 6, 16). The median LNY in the PS group was 11 (Q1, Q3: 6, 17), p < 0.001.
Conclusion
Despite differences in patient characteristics and external factors, we found no difference in LNY following ALND between patients who underwent NAC and those who had initial surgery. Efforts should be made to achieve equivalent LNY whether or not patients receive NAC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chung A, Giuliano A. Axillary staging in the neoadjuvant setting. Ann Surg Oncol. 2010;17(9):2401–10. https://doi.org/10.1245/s10434-010-1001-8.
Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15(7):2483–93. https://doi.org/10.1200/JCO.1997.15.7.2483.
Mamounas EP. Sentinel lymph node biopsy after neoadjuvant systemic therapy. Surg Clin North Am. 2003;83(4):931–42. https://doi.org/10.1016/S0039-6109(03)00032-X.
Kuerer HM, Sahin AA, Hunt KK, et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg. 1999;230(1):72–8. https://doi.org/10.1097/00000658-199907000-00011.
Axelsson CK, Mouridsen HT, Zedeler K. Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer. 1992;28A(8–9):1415–8. https://doi.org/10.1016/0959-8049(92)90534-9.
Kiricuta CI, Tausch J. A mathematical model of axillary lymph node involvement based on 1446 complete axillary dissections in patients with breast carcinoma. Cancer. 1992;69(10):2496–501. https://doi.org/10.1002/1097-0142(19920515)69:10%3c2496::aid-cncr2820691018%3e3.0.co;2-t.
Veronesi U, Luini A, Galimberti V, Marchini S, Sacchini V, Rilke F. Extent of metastatic axillary involvement in 1446 cases of breast cancer. Eur J Surg Oncol. 1990;16(2):127–33.
Rosenberger LH, Ren Y, Thomas SM, et al. Axillary lymph node dissection in node-positive breast cancer: Are ten nodes adequate and when is enough, enough? Breast Cancer Res Treat. 2020;179(3):661–70. https://doi.org/10.1007/s10549-019-05500-9.
Erbes T, Orlowska-Volk M, Zur Hausen A, et al. Neoadjuvant chemotherapy in breast cancer significantly reduces number of yielded lymph nodes by axillary dissection. BMC Cancer. 2014;14:4. https://doi.org/10.1186/1471-2407-14-4.
Lee MC, Plews R, Rawal B, Kiluk JV, Loftus L, Laronga C. Factors affecting lymph node yield in patients undergoing axillary node dissection for primary breast cancer: a single-institution review. Ann Surg Oncol. 2012;19(6):1818–24. https://doi.org/10.1245/s10434-011-2199-9.
Bélanger J, Soucy G, Sidéris L, et al. Neoadjuvant chemotherapy in invasive breast cancer results in a lower axillary lymph node count. J Am Coll Surg. 2008;206(4):704–8. https://doi.org/10.1016/j.jamcollsurg.2007.10.016.
Neuman H, Carey LA, Ollila DW, et al. Axillary lymph node count is lower after neoadjuvant chemotherapy. Am J Surg. 2006;191(6):827–9. https://doi.org/10.1016/j.amjsurg.2005.08.041.
Boughey JC, Donohue JH, Jakub JW, Lohse CM, Degnim AC. Number of lymph nodes identified at axillary dissection: effect of neoadjuvant chemotherapy and other factors. Cancer. 2010;116(14):3322–9. https://doi.org/10.1002/cncr.25207.
Funding
No funding was obtained for this project.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Fan, B., Romatoski, K., Pardo, J. et al. Evaluating Axillary Lymph Node Yield After Neoadjuvant Chemotherapy. Ann Surg Oncol 30, 107–111 (2023). https://doi.org/10.1245/s10434-022-12438-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-022-12438-8